Physician profile
Patrick B Murphy
NPI 1497703367
$8,310.30
in general payments reported to CMS, 2019-2025
22 companies · $637 in 2025
The $637 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,809 · 2020: $264 · 2021: $366 · 2022: $529 · 2023: $388 · 2024: $317 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $6,064.07 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $694.84 | 2019-2023 | Xarelto |
| Pfizer INC. | $356.28 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $183.97 | 2022-2024 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $141.72 | 2019-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $113.82 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $106.20 | 2024-2025 | Verquvo, Capvaxive |
| Amgen INC. | $97.92 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $84.44 | 2019-2025 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $63.92 | 2025 | Amvuttra |
| Amarin Pharma, INC. | $60.13 | 2021-2022 | |
| Philips North America LLC | $55.32 | 2025 | Pioneer, Labosys |
| Bayer Healthcare Pharmaceuticals INC. | $50.65 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.32 | 2022-2023 | Jardiance |
| Esperion Therapeutics, INC. | $35.22 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $34.76 | 2025 | Angio-Seal |
| Regeneron Healthcare Solutions, INC. | $32.32 | 2019 | |
| Scpharmaceuticals INC. | $26.98 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $24.49 | 2024 | Arcalyst |
| Getinge USA Sales, LLC | $17.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.66 | 2019 | |
| Vifor Pharma, INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.